Neurodiem, a new digital platform of independent, high-quality scientific content for UK neuro practitioners

16 Dec 2020

With the non-stop influx of scientific data in neurology, healthcare professionals often struggle to stay up to date on the latest developments by searching through multiple journals and pouring through lengthy articles in search of new advances.

To address the challenge, Biogen Inc. established a single, online platform that aggregates high-quality scientific content in 18 neurology topics, in digestible format. The service was developed by listening to neurologists’ needs through extensive desk research, interviews, prototype testing and ongoing user feedback to ensure the service is relevant and constantly improving.

Called Neurodiem , the non-promotional digital platform from Biogen Inc. is available in seven languages and is now live in the United Kingdom , United States, France, Germany, Italy, Spain, Austria, the Nordic countries, Canada, Japan and Brazil. The scientific information on the platform is entirely objective and independent from Biogen. It is selected, written, and published exclusively by independent scientific writers and editorial partners, who endure ongoing relationships with faculty from academic institutes, and hospitals worldwide.

In 2020, the platform features over 3000 daily summaries from key publications, exclusive presentations and interviews from over 70 key medical experts on emerging topics, real-time highlights from 13 international neurology conferences, and access to over 900 full-text articles from renowned neurology journals. To date, more than 11,000 healthcare professionals, including over 7000 neurologists, have joined Neurodiem worldwide.

Check out the video above on Neurodiem and register for free at to learn more.

Neurodiem is free and exclusive to healthcare professionals. Neurodiem is a service provided by Biogen MA Inc. The information presented on Neurodiem will in no way be selected, modified or altered by Biogen.